Cite
652O Randomized phase III VANCE study: Gemcitabine and carboplatin (GC) followed by Epstein Barr virus-specific autologous cytotoxic T lymphocytes (EBV-CTL) versus the same chemotherapy as first-line treatment for advanced nasopharyngeal carcinoma (NPC).
MLA
Toh, H. C., et al. “652O Randomized Phase III VANCE Study: Gemcitabine and Carboplatin (GC) Followed by Epstein Barr Virus-Specific Autologous Cytotoxic T Lymphocytes (EBV-CTL) versus the Same Chemotherapy as First-Line Treatment for Advanced Nasopharyngeal Carcinoma (NPC).” Annals of Oncology, vol. 33, Sept. 2022, p. S840. EBSCOhost, https://doi.org/10.1016/j.annonc.2022.07.776.
APA
Toh, H. C., Yang, M.-H., Wang, H.-M., Hsieh, C.-Y., Chitapanarux, I., Ho, K. F., Hong, R.-L., Ang, M.-K., Colevas, D., Sirachainan, E., Lertbutsayanukul, C., Ho, G. F., Samol, J., Huang, Z., Tan, C., Ding, C., & Myo, A. (2022). 652O Randomized phase III VANCE study: Gemcitabine and carboplatin (GC) followed by Epstein Barr virus-specific autologous cytotoxic T lymphocytes (EBV-CTL) versus the same chemotherapy as first-line treatment for advanced nasopharyngeal carcinoma (NPC). Annals of Oncology, 33, S840. https://doi.org/10.1016/j.annonc.2022.07.776
Chicago
Toh, H.C., M-H. Yang, H-M. Wang, C-Y. Hsieh, I. Chitapanarux, K.F. Ho, R-L. Hong, et al. 2022. “652O Randomized Phase III VANCE Study: Gemcitabine and Carboplatin (GC) Followed by Epstein Barr Virus-Specific Autologous Cytotoxic T Lymphocytes (EBV-CTL) versus the Same Chemotherapy as First-Line Treatment for Advanced Nasopharyngeal Carcinoma (NPC).” Annals of Oncology 33 (September): S840. doi:10.1016/j.annonc.2022.07.776.